Pfizer Ltd reported a healthy performance for the September quarter (Q2 FY26), posting a 19.4% year-on-year rise in net profit to ₹189 crore, compared to ₹158 crore in the same period last year. The growth was supported by strong sales momentum and improved operational efficiency.

The company's revenue from operations rose 9.1% YoY to ₹642.3 crore, reflecting steady demand across key therapeutic segments.

EBITDA for the quarter stood at ₹229.8 crore, up 21.5% from ₹189.2 crore last year, while EBITDA margins improved significantly to 35.8% from 32.1%, aided by cost optimisation.

The company highlighted that during the quarter ended March 31, 2025, it had received approvals from the Maharashtra Industrial Development Corporation (MIDC) for the assignment and sale of its leased land and

See Full Page